EUNETWORKS
9.9.2021 10:02:12 CEST | Business Wire | Press release
euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced that it has completed a strategic investment of critical fibre-based internet infrastructure linking London and Amsterdam, including the delivery of a new subsea high fibre count cable system named Scylla that is now in service. This is the first subsea cable system between the UK and the Netherlands since 1999.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210909005383/en/
euNetworks builds and invests in its city and long haul fibre networks to connect the key data centres and data centre hubs across the UK and Europe. The company builds Super Highways on long haul routes that are critical to Europe’s future international bandwidth needs and uses low loss fibre on these routes to deliver a low cost per bit long haul solution for its customers.
This latest state of the art, ultra high capacity fibre system extends euNetworks’ unique Super Highway network onto the Continent after delivering Super Highway 1 linking Dublin and London to Lowestoft in November 2019. euNetworks’ second Super Highway links Lowestoft via the new submarine cable Scylla to IJmuiden and then onto Amsterdam. Combined with euNetworks’ extensive metro networks in Dublin , Manchester , London and Amsterdam , the system enables any data centre to any data centre connectivity between all these metros on euNetworks’ owned and operated fibre, end-to-end.
Detailed design and permitting studies were initiated in August 2019, construction started in April 2020 and services were delivered to customers at the beginning of September 2021. This low loss network is entirely new fibre deployment. The terrestrial backhaul networks utilise new low-loss Corning SMF28 Ultra G657.A1 fibre cables and three entirely new amplification sites for the two cable landings and intermediate repeater in the UK. With existing sites and backhauls built over 20 years ago, these new facilities eliminate the unreliability of old infrastructure and provide scalable and power-efficient amplification housing, with significantly reduced long-run power demands.
Scylla itself is a non-hybrid 96 pair double-armoured sea cable, solely using Corning’s SMF28 ULL (ultra-low loss) G654.C pure silica fibre; giving all customers the benefit of future-proofed ultra-low attenuation on the 211km (cable landing station to cable landing station) unrepeatered system. This low attenuation is critical to achieving lowest cost per bit, directly driving greater bandwidth per fixed-cost transponder.
The North Sea has traditionally been a hostile environment for subsea cables, with a combination of high water current, a mobile sandy seabed and intense fishing presenting regular service challenges due to cable cuts. euNetworks planned and developed Scylla using new technology to both minimise these risks and also to lower the environmental impact from the cable laying process. During planning and mapping, the seabed was modelled to identify sand wave movement together with fishing intensity in areas with historic cable strikes. This highlighted potential areas of risk for the cable lay and subsequent path modification or planned deeper cable burial. euNetworks also used an innovative cable laying technique for telecom cables, utilising a CAPJET trenching system – a high powered water jet more commonly used for power cables – to create the 2-3 metre deep but narrow trench for the cable to lay in. The CAPJET uniquely enables greater precision and ‘micro-routing’ during the cable lay process. The remotely operated system with on-board telemetry allows for steering in real-time. The low ploughing tension allows for quick manoeuvrability, delivering a finer cable lay plan, burial between the troughs in natural sand formations and subsequent deeper burying of the cable over time. This contrasts with a traditional ploughed burial, which may achieve theoretically similar depths, but must follow much straighter paths over sand waves with amplitudes of 8m and pitches of 12o . Such an approach creates risks to the initial lay, uneven burial depth and still leaves the probability of the cable becoming unburied over time. As well as ensuring deeper burial naturally, laying the cable with precision and less impact on the seabed, euNetworks has buried Scylla up to 3 metres deep versus typical 0.7 metres for existing systems, offering better protection against strikes both today and in the future.
On land the company has also designed and planned this new network with sustainability in mind. The route is designed with optimal spacing and attenuation loss between amplifier sites, meaning less ILA/PoP sites compared to other routes in service. The use of modern fibre types plus a reduction in ILA sites along the route meant less construction during deployment, less resources and less power consumption in service. In addition, the technology used within the new ILA sites is new, with more efficient air conditioning monitoring the air being drawn in and hence using less power when cooling. Overall this approach delivers a much lower power consumption per bit and delivers an optimised low carbon footprint network infrastructure.
“This Super Highway is an important investment in Western European bandwidth infrastructure,” said Brady Rafuse, Chief Executive Officer of euNetworks. “We’ve delivered the first new subsea cable on this important route in 20 years and delivered a unique route running between London and Amsterdam to support the many businesses whose connectivity requirements continue to grow. Critically for our customers, this network development continues our approach of delivering highly scalable, owned and operated fibre based sustainable infrastructure to support their needs.”
“We extend our thanks to all those who have worked with us on this project. We look forward to continuing to work closely with our customers in these regions and across our networks, delivering the bandwidth experience and scale they need,” said Rafuse.
About euNetworks
euNetworks is a bandwidth infrastructure company, owning and operating 17 fibre based metropolitan networks connected with a high capacity intercity backbone covering 51 cities in 15 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 450 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs. For further information visit eunetworks.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005383/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
